Impact of Dose to Cardiac Substructures on Survival in Patients With Esophageal Cancer Treated With Radiotherapy or Chemoradiotherapy (SATIATION)
NCT ID: NCT05996276
Last Updated: 2024-08-09
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
150 participants
OBSERVATIONAL
2023-08-01
2024-09-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
The cardiac toxicity of radiotherapy in the treatment of thoracic tumor localizations is well documented, however, more and more studies are calling for the use of dosimetric parameters related to cardiac sub-structures to be integrated into clinical practice, rather than considering the heart as a whole.
With this in mind, the aim of this study is to define the parameters, particularly dosimetric ones linked to cardiac sub-structures, influencing survival in patients treated with exclusive radiotherapy or radiochemotherapy for esophageal cancer.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Detection of (Sub)Clinical Toxicity in Irradiated vs. Non-irradiated Surgically Treated Esophageal Cancer Patients: a Pilot Study (CROSS SECT)
NCT03396614
Postoperative Radiotherapy Followed by Immunotherapy for Locally Advanced Esophageal Carcinoma
NCT05937438
Radiochemotherapy With and Without Dose Escalation in Patients Presenting Locally Advanced or Inoperable Carcinoma of the Oesophagus
NCT01348217
Surgery With or Without Radiation Therapy and Chemotherapy in Treating Patients With Esophageal Cancer
NCT00047112
RCT on the Combined Modality Treatment of Squamous Cell Carcinoma of the Esophagus
NCT00559351
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
The cardiac toxicity of radiotherapy in the treatment of thoracic tumor localizations is well documented, however, more and more studies are calling for the use of dosimetric parameters related to cardiac sub-structures to be integrated into clinical practice, rather than considering the heart as a whole.
Although most of these data have been studied in populations with long-term follow-up, such as breast cancer, cardiac toxicity and the reduced survival it entails are also found in diseases such as esophageal cancer.
With this in mind, the aim of this study is to define the parameters, particularly dosimetric ones linked to cardiac sub-structures, influencing survival in patients treated with exclusive radiotherapy or radiochemotherapy for esophageal cancer.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
RETROSPECTIVE
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Histologically or cytologically proven esophageal cancer
* Localized or locally advanced esophageal cancer treated with radiochemotherapy or exclusive radiotherapy
* Tumor dose ≥ 50 Gy
* Non-opposition of living patients formulated
* Patient affiliated to a social security scheme
Exclusion Criteria
* Patient treated with upfront surgery
* Tumor dose \< 50 Gy
* Other concomitant neoplasia
* Metastatic patient
* Refusal to participate
* Patient under legal protection (guardianship, curatorship, etc...)
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
University Hospital, Brest
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Vincent Bourbonne, MD, PhD
Role: PRINCIPAL_INVESTIGATOR
Radiation Oncology Department, Brest University Hospital
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Chu Brest
Brest, , France
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
29BRC23.0144 - SATIATION
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.